DSCSA Track-and-Trace Requirements for US Buyers Sourcing Indian Pharmaceuticals

Understanding DSCSA Requirements for Indian Generic Imports

The Drug Supply Chain Security Act (DSCSA), enacted in 2013 and phased in through 2023, fundamentally transformed how pharmaceutical products move through the United States supply chain. For distributors, importers, and wholesalers sourcing generic medicines from India, understanding DSCSA compliance is not optional—it is a legal prerequisite to lawful distribution within the US market.

The DSCSA establishes a national system for tracing prescription drugs as they move through the supply chain, from manufacturer to dispenser. This regulatory framework applies equally to domestically manufactured products and imported pharmaceuticals, including the high-quality generics produced by Indian manufacturing partners. US importers must ensure that every transaction meets serialization, verification, and documentation standards set by the Food and Drug Administration (FDA).

Core DSCSA Obligations for Pharmaceutical Importers

Under DSCSA, authorized distributors must maintain complete transaction histories, transaction information, and transaction statements for all pharmaceutical products. When importing generic medicines from India, your Indian supplier—working through a US-registered importer of record—must provide specific data elements at the package level.

Transaction Information (TI) must include the proprietary or established name of the product, strength and dosage form, National Drug Code (NDC), container size, number of containers, lot number, transaction date, and shipment date. Transaction History (TH) documents the chain of ownership from the initial manufacturer through each subsequent owner. Transaction Statement (TS) is a signed declaration that the entity providing the product is authorized, received it from an authorized source, and did not knowingly ship suspect or illegitimate product.

For distributors working with Tuli Enterprise and our network of manufacturing partners across India, we coordinate the preparation of these documents to align with DSCSA standards. Our partners maintain detailed batch records, serialization data, and chain-of-custody documentation that form the foundation of compliant TI/TH/TS packages.

Product Serialization and Verification Requirements

Since November 2023, DSCSA requires product-level serialization for most prescription drugs entering US commerce. Each saleable unit must carry a unique product identifier comprising the NDC, serial number, lot number, and expiration date, encoded in a 2D Data Matrix barcode.

Indian manufacturers supplying the US market have invested significantly in serialization infrastructure. When you source therapeutic categories such as antibiotics, antihypertensives, or antidiabetics from India, verify that your manufacturing partner can apply compliant serialization at the packaging line. Tuli Enterprise works exclusively with facilities equipped with modern serialization systems that generate unique serial numbers, apply GS1-compliant barcodes, and maintain aggregation data linking individual units to cases and pallets.

Verification obligations require trading partners to investigate and resolve suspect products. Distributors must have systems in place to verify product identifiers, quarantine suspect product, and report to FDA within required timeframes. Your Indian supplier should provide serialization data in EPCIS format or other interoperable standards to facilitate verification through your warehouse management or track-and-trace systems.

Import Documentation Beyond DSCSA

DSCSA compliance layers atop existing FDA import requirements. Generic medicines entering the United States must still meet all FDA regulatory standards, including approval under an Abbreviated New Drug Application (ANDA) or listing in the FDA Orange Book for therapeutically equivalent products.

Your Indian exporter should provide a Certificate of Pharmaceutical Product (COPP) issued by the Indian regulatory authority, confirming that the product is approved for marketing in India and manufactured at facilities meeting quality standards. A Certificate of Analysis (CoA) for each batch demonstrates compliance with pharmacopoeial specifications. Free Sale Certificates confirm the product is freely sold in the country of origin without restrictions.

Tuli Enterprise routinely prepares comprehensive documentation packages for US importers, including stability data, manufacturing site master files, and detailed product specifications. We understand that US Customs and Border Protection (CBP) and FDA field offices scrutinize pharmaceutical imports closely, and incomplete documentation causes costly delays at port of entry.

Authorized Trading Partner Status

DSCSA restricts pharmaceutical distribution to "authorized" entities. Manufacturers, repackagers, wholesale distributors, and dispensers must be properly licensed and registered. When importing from India, ensure your supplier works through a US-registered importer of record who holds appropriate state wholesale distributor licenses.

Tuli Enterprise partners with licensed US importers and distributors who maintain state licensure in their operating jurisdictions. We verify that our contract manufacturing partners are registered with FDA, hold Drug Master Files where applicable, and operate facilities that have undergone FDA inspection or are listed in FDA's establishment database.

Maintaining authorized status requires ongoing compliance. Distributors must provide trading partner information upon request, maintain secure systems to prevent unauthorized access to prescription drugs, and implement robust processes to detect and investigate suspect or illegitimate product.

Practical Steps for DSCSA-Compliant Importing

Establish clear contractual terms with your Indian supplier regarding serialization format, data exchange protocols, and documentation timelines. Specify that all shipments must include compliant TI/TH/TS documentation and serialized product identifiers before goods leave India.

Invest in track-and-trace technology capable of receiving, storing, and transmitting serialization data. Many US distributors use enterprise systems that integrate with customs brokerage, warehouse management, and sales order processing to maintain unbroken chain of custody records.

Conduct due diligence on manufacturing partners. Request facility inspection reports, quality certifications, and evidence of serialization capability. Tuli Enterprise provides transparency into our partner network, sharing facility credentials and regulatory standing to help you satisfy DSCSA authorized trading partner verification obligations.

Develop standard operating procedures for handling suspect product. DSCSA requires distributors to quarantine and investigate any product that appears counterfeit, diverted, stolen, or otherwise suspect. Train your receiving and quality teams to recognize red flags such as damaged serialization labels, mismatched lot numbers, or products offered significantly below market price.

Stay current with FDA guidance. The agency continues to issue draft and final guidance documents clarifying DSCSA expectations, including interoperability standards, verification processes, and enhanced drug distribution security. Regularly review FDA's DSCSA webpage and participate in industry working groups to anticipate evolving requirements.

Why Indian Generics Remain Competitive Under DSCSA

Despite the compliance complexity, Indian pharmaceutical manufacturers remain highly competitive suppliers to the US market. India's robust regulatory framework, mature manufacturing infrastructure, and deep experience with international quality standards position Indian generics favorably in the post-DSCSA environment.

Leading Indian facilities have achieved FDA approval for hundreds of ANDAs and undergo regular FDA inspections. The serialization investments required by DSCSA align with global trends toward supply chain transparency, and Indian manufacturers have adapted quickly. For US distributors, sourcing from India through experienced export partners like Tuli Enterprise offers access to cost-effective, high-quality generics with full DSCSA compliance support.

Our regulatory insights and documentation expertise help bridge the gap between Indian manufacturing excellence and US regulatory expectations, ensuring your imports meet both DSCSA traceability requirements and broader FDA quality standards.

Request DSCSA-Compliant Generic Supply from India

Tuli Enterprise supports US pharmaceutical importers and distributors with comprehensive DSCSA compliance assistance. We coordinate serialization, prepare complete transaction documentation, and ensure our manufacturing partners meet authorized trading partner standards. Our team understands the intersection of FDA import regulations, DSCSA traceability requirements, and practical supply chain operations.

Whether you need serialized antibiotics, cardiovascular medicines, or other therapeutic categories, we provide the documentation, transparency, and quality assurance US buyers require. Contact our export team via WhatsApp at +91-9654308142 or email [email protected] to discuss your DSCSA-compliant generic medicine requirements. We'll provide detailed product specifications, serialization capabilities, regulatory documentation, and competitive pricing for your US distribution operations.